Phone (303) 825-TUCC (8822)      Toll-Free (877) 825-8898

Urology News

Clinical advancements in the field of urology are featured in the news media every day. This section provides patients and physicians with the most up-to-date information on recent urologic advancements around the world.

* Please Note - TUCC does not necessarily advocate any of the treatment methods listed in the articles below. This news feed is provided as a resource for those interested in the latest urologic research occurring around the world.

  • July 17, 2014
    Late-stage prostate cancer increasing among younger men

    Diagnoses of late-stage prostate cancer among younger men are on a surprising increase, with a nearly sixfold rise in diagnoses over two decades — too much of an increase to link solely to better screening, according to a team of researchers at the University of Michigan Comprehensive Cancer Center.

    Some of these cases turn out to be very aggressive and these men can present with cancer that has already spread to lymph nodes and bone.

  • July 3, 2014
    Free Hepatitis C Screenings Offered in Denver

    Avella Specialty Pharmacy, in collaboration with the American Liver Foundation and Denver Colorado AIDS Project, will offer free Hepatitis screenings for individuals considered high risk at its Denver-based facility on July 28th in support of World Hepatitis Day.  Hepatitis C can be detected through a simple blood test that identifies antibodies to the virus. Early detection of the Hepatitis C Virus (HCV) is critical since many individuals that have the condition exhibit no symptoms and don’t realize they are infected. Early detection can also help prevent serious complications from this disease including liver damage, cirrhosis and even liver cancer.

  • June 4, 2014
    New approach to treating prostate cancer may boost survival

    Adding the chemotherapy drug docetaxel to standard hormone-depleting therapy may extend the lives of men with advanced prostate cancer, a new study finds.

    The study was to be presented Sunday in Chicago at the annual meeting of the American Society of Clinical Oncology (ASCO).

  • May 17, 2014
    Stanford scientists identify source of most cases of invasive bladder cancer

     A single type of cell in the lining of the bladder is responsible for most cases of invasive bladder cancer, according to researchers at the Stanford University School of Medicine.

    Their study, conducted in mice, is the first to pinpoint the normal cell type that can give rise to invasive bladder cancers. It's also the first to show that most bladder cancers and their associated precancerous lesions arise from just one cell, and explains why many human bladder cancers recur after therapy.

  • May 14, 2014
    Low testosterone may indicate prostate cancer progression

    Low testosterone levels may indicate disease worsening in men diagnosed with low-risk prostate cancer who are being evaluated by active surveillance, according to a new study by Pontificia Universidad Católica de Chile in Santiago, Chile and Beth Israel Deaconess Medical Center in Boston. The results were published in BJU International.

    Of a total of 154 men undergoing active surveillance followed for a median of 38 months, 35% (54 men) progressed to active treatment. All of the men were initially diagnosed with low-risk prostate cancer. Those men who transitioned to active treatment had significantly lower free testosterone levels compared with those who continued to have classified low-risk disease (P = .03). The median age of the men was 62, and all were enrolled into the prospective cohort between 2000 and 2012.

  • May 2, 2014
    Electronic nose sniffs out prostate cancer using urine samples

     Novel noninvasive technique successfully discriminates between prostate cancer and benign disease in proof of principle study, paving the way for easy and early diagnosis, reports the Journal Of Urology

  • April 7, 2014
    World Experts and Androgen Study Group Petition JAMA to Retract Misleading Article on Testosterone Therapy

    Three professional medical societies and a highly distinguished international group of over 130 scientists and concerned physicians have petitioned the Journal of the American Medical Association to retract the article that precipitated recent concerns regarding cardiovascular risks with testosterone therapy.  In a letter addressed to the editor-in-chief of JAMA, Dr. Howard Bauchner, the group cites "gross data mismanagement," rendering the article "no longer credible."

  • March 25, 2014
    SBRT (Cyberknife) for prostate cancer may result in more complications

    Patients treated with a newer, faster, and less expensive type of radiotherapy also have higher rates of urinary complications, according to a new study published in the Journal of Clinical Oncology.

    The newer therapy approach, called stereotactic body radiation therapy (SBRT), is already beginning to replace the older standard approach, intensity-modulated radiation therapy (IMRT). However, the new study by James B. Yu, MD, of the Yale School of Medicine and Yale Cancer Center, and colleagues at the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale Cancer Center shows that SBRT is associated with increased toxicity that offsets the savings of using this newer form of radiotherapy.

  • March 10, 2014
    Surgery may be best for young men with prostate cancer

    Younger men who have been diagnosed with prostate cancer may do well to consider surgery over so-called “watchful waiting,” a new study shows.

    The new research, published yesterday in the New England Journal of Medicine,  is unlikely to end the long-running debate in the medical community over if and when surgery to remove the prostate is needed — particularly since the men in the study were diagnosed before the sensitive prostate-specific antigen (PSA) test was widely implemented to detect prostate cancer in its early stages.

    The findings are the latest to come out of a 23-year-long, ongoing study comparing radical prostatectomy versus watchful waiting in 695 men who had been diagnosed with localized prostate cancer.

  • February 6, 2014
    Drug shows promise in advanced prostate cancer when used before chemotherapy

    The prostate cancer drug Xtandi prolonged lives and delayed tumor progression when used before chemotherapy in a study of men with advanced cases of the disease, researchers said on Tuesday.

    The study results are expected to open up a broader market for Xtandi, which was developed by Medivation and Astellas Pharma, and open a new front in its competition with Johnson & Johnson’s blockbuster drug Zytiga.

Request an Appointment

TUCC is contracted with all major insurance companies. We look forward to providing you with clinically advanced, compassionate urologic care.

read more »